Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
CONCLUSIONS: Trastuzumab plus TKI was better than trastuzumab monotherapy for treating different stages of HER2-positive breast cancer. The safety of trastuzumab plus TKI anti-HER2 therapy was controllable. The different efficacies of TKIs combined with trastuzumab may be related to the mechanism of action of the different TKIs, needing further investigations.PMID:37640146 | DOI:10.1016/j.bbcan.2023.188969
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Lixi Li Di Zhang Yun Wu Jiayu Wang Fei Ma Source Type: research
More News: Biochemistry | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | HER2 | Herceptin | Hormones | Neoadjuvant Therapy | Science | Study